Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)-Reference-Cited by-同舟云学术

Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)

Published:2007-02-15 Issue:1 Volume:107 Page:87-94
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Takei Hiroyuki,Suemasu Kimito,Inoue Kenichi,Saito Tsuyoshi,Okubo Katsuhiko,Koh Junichi,Sato Kazuhiko,Tsuda Hitoshi,Kurosumi Masafumi,Tabei Toshio

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-007-9529-4.pdf

Reference33 articles.

1. Wolff AC, Davidson NE (2000) Primary systemic therapy in operable breast cancer. J Clin Oncol 18:1558–1569

2. Freedman OC, Verma S, Clemons MJ (2005) Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 31:1–17

3. Strasser-Weippl K, Goss PE (2005) Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 23:1751–1759

4. Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18:3758–3767

5. Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase II study of the International Letrozole Breast Cancer Study Group. J Clin Oncol 19:2596–2606

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer;Future Oncology;2024-07-29

2. Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer;Journal of Nippon Medical School;2021-08-25

3. Actaea racemosa L. extract inhibits steroid sulfation in human breast cancer cells: Effects on androgen formation;Phytomedicine;2020-12

4. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines;Breast Cancer Research;2020-07-20

5. Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer;World Journal of Clinical Cases;2019-08-06